{"id":"W4298850272","doi":"","title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","year":2015,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Etanercept; Tofacitinib; Medicine; Placebo; Psoriasis; Dermatology; Internal medicine; Alternative medicine; Tumor necrosis factor alpha; Rheumatoid arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00512502,0.002048087,0.003984315,0.0004957502,0.0006154103,0.001545942,0.001134633,0.002770186,0.01078437],"category_scores_gemma":[0.00339362,0.0007877395,0.003162512,0.0005737831,0.001359325,0.001196352,0.0004749851,0.003481204,0.001169719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008064928,"about_ca_system_score_gemma":0.001605995,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006893951,"about_ca_topic_score_gemma":0.001444319,"domain_scores_codex":[0.9984458,0.0009835368,0.00009956311,0.0001802556,0.0001115509,0.0001793871],"domain_scores_gemma":[0.9979799,0.0007811699,0.0004671755,0.0001646291,0.0001142012,0.000492876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9874051,0.003593754,0.0001938288,0.0004929418,0.0005126306,0.00003031565,0.00003254253,0.0001448836,0.001410073,0.00007589129,0.0004904312,0.005617609],"study_design_scores_gemma":[0.9790025,0.01987498,0.0003969927,0.00002252618,0.0001536109,0.0000192049,0.000006790576,0.0001352022,0.00008192158,0.00009749688,0.000203423,0.000005417338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9637229,0.01112146,0.001690033,0.001890007,0.001412778,0.01344587,0.002080358,0.0002724777,0.004364141],"genre_scores_gemma":[0.9635371,0.005582731,0.003160588,0.002934664,0.001355049,0.01782651,0.001336131,0.00005748063,0.00420968],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01078437,"threshold_uncertainty_score":0.03607738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03580989490834927,"score_gpt":0.2836305235767836,"score_spread":0.2478206286684344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}